Joshua Silverwood - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Joshua Silverwood's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Joshua Silverwood
Verified
News Reporter, Medical Device Network
United Kingdom
Beats
Fintech , Cryptocurrency , DeFi
Law
Content
By Joshua Silverwood Verified| Clinical Trials Arena Verified A first-in-human trial of Arvinas’ investigational Parkinson’s’ disease therapy, ARV-102, has been able to demonstrate a drop in the multifunctional protein that has been associated with the disease whilst also surpassing the blood-brain barrier. The Phase I single ascending dose (SAD) and multiple ascending dose (MAD) trial (EUCT-2023-507910-28-00) found ARV-102, a proteolysis targeting chimaera (PROTAC) therapy, led to a drop in leucine-rich repeat kinase 2 (LRRK2) across healthy volunteers
By Joshua Silverwood Verified| Clinical Trials Arena Verified Lundbeck’s receptor superagonist designed to treat seizures associated with developmental and epileptic encephalopathies (DEEs) has seen a 61.2% reduction in total seizures in a Phase Ib/IIa trial
By Joshua Silverwood Verified| Clinical Trials Arena Verified California-based biotech BeiGene has terminated the clinical development programme for its lung cancer therapy ociperlimab, after an independent committee ruled that it was unlikely to meet its primary endpoint of impacting overall survival (OS) in a Phase III trial
Company Info
Medical Device Network
Medical Device Network is an industry information platform focused on the medical device sector. It provides news, analysis, and directories related to medical device supply chains, regulatory issues, and market trends. The platform serves as a resource for professionals in the industry, offering insights and listings of medical device manufacturers and service providers. Its revenue model likely includes advertising and lead generation through company profiles and sector reports.
'+1 646-625-7388